keyword
MENU ▼
Read by QxMD icon Read
search

capecitabine

keyword
https://www.readbyqxmd.com/read/29344235/metronomic-chemotherapy-remodel-cancer-associated-fibroblasts-to-decrease-chemoresistance-of-gastric-cancer-in-nude-mice
#1
Chao Wang, Wenqi Xi, Jinling Jiang, Jun Ji, Yingyan Yu, Zhenggang Zhu, Jun Zhang
The present study aimed to evaluate whether capecitabine or 5-fluorouracil (5-Fu) chemotherapy with the metronomic pattern may cause significant chemoresistance compared with the traditional pattern, and whether CAFs are involved in drug resistance. SGC-7901 cells were subcutaneously injected into the nude mice, and the mice were divided into five groups: The control group, intraperitoneally injected with normal saline; the 5-Fu conventional dose group [5-Fu maximum tolerated dose (MTD) group], intraperitoneally injected with 50 mg/kg, twice per week for 2 weeks, with an 1-week discontinuation for 6 weeks; the capecitabine conventional dose group (capecitabine MTD group), intragastric 500 mg/kg, twice per week for 2 weeks, with a 1-week discontinuation for 6 weeks; the 5-Fu metronomic group [5-Fu low-dose metronomic (LDM) group], intraperitoneally injected with 15 mg/kg, twice a week for 6 weeks; and the capecitabine metronomic group (capecitabine LDM group), intragastric administration at 200 mg/kg, twice a week for 6 weeks...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29342859/multinuclear-nmr-measurements-and-dft-calculations-for-capecitabine-tautomeric-form-assignment-in-a-solution
#2
Piotr Cmoch, Piotr Krzeczyński, Andrzej Leś
The molecular structure of capecitabine (a widely applied prodrug of 5-fluorouracil) was studied by multinuclear NMR measurements and DFT quantum mechanical calculations. One or two tautomeric forms in a solution were detected depending on the solvent used. In the organic solvents, a mixture of two forms of capecitabine was observed: carbamate and imine tautomers. In the aqueous solution, only the carbamate form was found. The methylation of capecitabine yields mainly two products in different proportions: N³-methylcapecitabine and N⁷-methylcapecitabine...
January 13, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29340835/repurposed-fda-approved-drugs-targeting-genes-influencing-aging-can-extend-lifespan-and-healthspan-in-rotifers
#3
Terry W Snell, Rachel K Johnston, Amelia B Matthews, Hongyi Zhou, Mu Gao, Jeffrey Skolnick
Pharmaceutical interventions can slow aging in animals, and have advantages because their dose can be tightly regulated and the timing of the intervention can be closely controlled. They also may complement environmental interventions like caloric restriction by acting additively. A fertile source for therapies slowing aging is FDA approved drugs whose safety has been investigated. Because drugs bind to several protein targets, they cause multiple effects, many of which have not been characterized. It is possible that some of the side effects of drugs prescribed for one therapy may have benefits in retarding aging...
January 16, 2018: Biogerontology
https://www.readbyqxmd.com/read/29340011/capecitabine-for-primary-breast-cancer
#4
EDITORIAL
Masakazu Toi, Norikazu Masuda, Soo-Jung Lee
No abstract text is available yet for this article.
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29337636/new-onset-cardiovascular-morbidity-in-older-adults-with-stage-i-to-iii-colorectal-cancer
#5
Kelly M Kenzik, Courtney Balentine, Joshua Richman, Meredith Kilgore, Smita Bhatia, Grant R Williams
Purpose We sought to determine the long-term risk of cardiovascular disease (CVD)-stroke and myocardial infarction-and congestive heart failure (CHF) in older patients with colorectal cancer, as well as to understand the roles that preexisting comorbidities and cancer therapy play in increasing this risk. Patients and Methods We evaluated individuals from the SEER-Medicare database with incident stage I to III colorectal cancer at age older than 65 years between January 1, 2000, and December 31, 2011 (n = 72,408) and compared these patients with a matched cohort of Medicare patients without cancer (n = 72,408)...
January 16, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29336052/rapidly-developing-heart-failure-from-capecitabine-cardiotoxicity-a-case-study
#6
Paurush Ambesh, Kaveh Zivari, Chukwudi Obiagwu, Vijay Shetty, Stephan Kamholz, Gerald Hollander, Jacob Shani
No abstract text is available yet for this article.
January 16, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29332339/p21-does-but-p53-does-not-predict-pathological-response-to-preoperative-chemoradiotherapy-in-locally-advanced-rectal-cancer
#7
Suzana Stojanovic-Rundic, Radmila Jankovic, Marjan Micev, Vladimir Nikolic, Ivan Popov, Dusica Gavrilovic, Vesna Plesinac-Karapandzic, Aleksandra Djuric-Stefanovic, Zoran Krivokapic, Sinisa Radulovic
PURPOSE: Preoperative chemoradiotherapy (CRT) is the standard treatment option in locally advanced rectal cancer. The tumor response is assessed through tumor and nodal downstaging and the tumor regression grade. Currently, there is no method to predict a tumor response to CRT. We aimed to evaluate whether p21 and p53 expressions could be a reliable predictors of pathological response to CRT. METHODS: Fifty patients with locally advanced rectal cancer were treated with preoperative radiotherapy combined with mitomycin C and capecitabine...
November 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29330005/a-phase-i-study-of-irinotecan-capecitabine-xeloda-and-oxaliplatin-in-patients-with-advanced-colorectal-cancer
#8
Jean Maroun, Horia Marginean, Derek Jonker, Christine Cripps, Rakesh Goel, Timothy Asmis, Rachel Goodwin, Gabriela Chiritescu
BACKGROUND: The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC). PATIENTS AND METHODS: Patients received oxaliplatin followed by irinotecan as intravenous infusions on day 1, with oral capecitabine taken twice daily (BID) on days 2 to 15 of a 3-week cycle...
December 15, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29323560/the-prospects-for-combination-therapy-with-capecitabine-in-the-rapidly-evolving-treatment-landscape-of-renal-cell-carcinoma
#9
Mehmet Asim Bilen, Jennifer Wilkinson-Carlisle, Guru Sonpavde
Although significant advances have been made in the treatment of advanced renal cell carcinoma (RCC), patients still develop resistance to standard therapies and require the administration of subsequent lines of treatment. New therapeutic approaches are thus imperative to improve the prognosis for patients with RCC. Areas covered: Based on the current literature, we summarize the treatment of metastatic RCC, including the use of cytotoxic chemotherapy, in this review article. We also review the existing scientific literature regarding the role of capecitabine in the treatment of RCC...
January 11, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29308947/predictive-factors-of-thromboembolic-complications-in-patients-with-esophagogatric-adenocarcinoma-undergoing-preoperative-chemotherapy
#10
George Papaxoinis, Konstantinos Kamposioras, Theodora Germetaki, Jamie M J Weaver, Sofia Stamatopoulou, Magdy Nasralla, Zoe Kordatou, Vikki Owen-Holt, Alan Anthoney, Wasat Mansoor
BACKGROUND: Thromboembolic events (TEEs) represent a significant treatment and disease complication for cancer patients. In the present study we assessed the incidence of TEEs in patients receiving preoperative chemotherapy for esophagogastric adenocarcinoma. The risk factors for TEE development and their impact on prognosis were further analyzed. MATERIAL AND METHODS: Data from 590 patients with esophagogastric adenocarcinoma, who received preoperative epirubicin-cisplatin with capecitabine (ECX) or 5-fluorouracil (ECF) between 2009 and 2016 in three UK hospitals were retrospectively collected...
January 8, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29303645/capecitabine-related-neurotoxicity-presenting-as-oromandibular-dystonia
#11
Ali Cengiz, Muhsin Nuh Aybay, Saim Furkan Sarıcı, Vefa Öner, Fatma Zeynep Arslan, Arzu Cengiz
No abstract text is available yet for this article.
January 5, 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29302858/subgroup-analysis-of-patients-with-her2-negative-metastatic-breast-cancer-in-the-second-line-setting-from-a-phase-3-open-label-randomized-study-of-eribulin-mesilate-versus-capecitabine
#12
Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé
This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and ≤ 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m2 on days 1-14 (21-day cycles)...
January 4, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29299356/fluoropyrimidine-induced-cardiac-toxicity-challenging-the-current-paradigm
#13
Suparna C Clasen, Bonnie Ky, Rupal O'Quinn, Bruce Giantonio, Ursina Teitelbaum, Joseph R Carver
Background: Fluoropyrimidine chemotherapy [5-fluorouracil (5-FU) and capecitabine] are commonly used agents in the treatment of various solid malignancies. However, their use has been limited by cardiac toxicity, presenting as a wide spectrum of asymptomatic (e.g., EKG changes) and symptomatic (e.g., chest pain) manifestations related to coronary vasospasm leading to myocardial ischemia. Historically, patients with suspected coronary vasospasm have been treated with traditional acute ischemic workup and various combinations of anti-anginal therapies...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29299353/capecitabine-and-oxaliplatin-as-first-and-second-line-treatment-for-locally-advanced-and-metastatic-pancreatic-ductal-adenocarcinoma
#14
Andrea Bullock, Keith Stuart, Susanna Jacobus, Thomas Abrams, Raymond Wadlow, Michael Goldstein, Rebecca Miksad
Background: There are limited treatment options available for patients with advanced pancreatic ductal adenocarcinoma (PDAC). We conducted a phase II study evaluating the efficacy and safety of capecitabine/oxaliplatin (CAPOX) in patients with locally advanced and metastatic PDAC treated in the first and second lines. Methods: Forty subjects with advanced PDAC and ECOG performance status ≥2 were enrolled. Treatment consisted of capecitabine 2,000 mg/m2 orally in two divided doses daily for 14 days and oxaliplatin 130 mg/m2 intravenously day 1 every 21 days...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29275610/-effects-of-oridonin-combined-with-capecitabine-on-the-proliferaction-of-mda-mb-231-human-breast-cancer-cells
#15
H P Lu, F F Ma, J R Gong, B Wang
Objective: To investigate the effects of oridonin combined with capecitabine on the proliferaction of MDA-MB-231 human breast cancer cells. Methods: Effect of different concentrations(10, 20 and 40 μmol/L)of oridonin, capecitabine and their combination on the proliferation of MDA-MB-231 cells after incubation for 24 or 48 h was studied. Then, the effect of 5 μmol/L of oridonin, capecitabine and their combination on cell colony formation was detected. Finally, influence of 20 μmol/L of oridonin, capecitabine and their combination on morphological alteration of nucleus, cell cycle and apoptosis was explored...
December 12, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29274446/a-progressively-enlarging-cerebellar-hematoma-concurrent-with-t-dm1-treatment-case-report
#16
Marcelo D Vilela, William T Longstreth, Hugo As Pedrosa, Gabriel Ob Gil, Juliano M Duarte, Marco Antonio D Filho
BACKGROUND: Trastuzumab emtansine, an antibody-drug conjugate commonly abbreviated as T-DM1, is accepted as an effective therapy for trastuzumab-resistant metastatic HER2-positive breast cancer. T-DM1 significantly increases progression-free and overall survival when compared to lapatinib plus capecitabine in patients with HER2-positive breast cancer previously treated with trastuzumab and a taxane. Among the common side effects related to T-DM1, thrombocytopenia and mucosal hemorrhage are seen, although they are infrequently judged to be clinically significant...
December 20, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/29273261/genotype-driven-phase-i-study-of-weekly-irinotecan-in-combination-with-capecitabine-based-neoadjuvant-chemoradiation-for-locally-advanced-rectal-cancer
#17
Ji Zhu, Xinxiang Li, Yunzhu Shen, Yun Guan, Weilie Gu, Peng Lian, Weiqi Sheng, Sanjun Cai, Zhen Zhang
PURPOSE: We aimed to identify the maximum tolerated dose (MTD) of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation according to the UGT1A1∗28 genotype in patients with locally advanced rectal cancer. PATIENTS AND METHODS: Patients with clinical stage T3-4, N0-2 who were eligible for preoperative chemoradiotherapy were screened for the UGT1A1∗28 genotype. Twenty-six patients with either the ∗1∗1 or ∗1∗28 genotype were eligible for dose escalation of irinotecan, and patients with a ∗28∗28 genotype were excluded...
December 19, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29258457/photosensitive-lichenoid-skin-reaction-to-capecitabine
#18
Rena A Shah, Daniel D Bennett, Mark E Burkard
BACKGROUND: Capecitabine is an oral prodrug of fluorouracil, which is a common agent used in the management of many solid tumor malignancies. Dermatologic reaction is common with various chemotherapy agents but is not commonly reported in the use of capecitabine. When adverse reactions of rashes occur, the offending agent is typically removed. We report here an unusual case of photosensitive lichenoid rash due to capecitabine which is managed conservatively without major alteration in treatment...
December 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29249005/metronomic-capecitabine-as-second-line-treatment-for-hepatocellular-carcinoma-after-sorafenib-discontinuation
#19
Franco Trevisani, Giovanni Brandi, Francesca Garuti, Maria Aurelia Barbera, Raffaella Tortora, Andrea Casadei Gardini, Alessandro Granito, Francesco Tovoli, Stefania De Lorenzo, Andrea Lorenzo Inghilesi, Francesco Giuseppe Foschi, Mauro Bernardi, Fabio Marra, Rodolfo Sacco, Giovan Giuseppe Di Costanzo
PURPOSE: Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcinoma (HCC). METHODS: 117 patients undergoing MC were compared to 112 patients, eligible for this treatment, but undergoing best supportive care (BSC) after sorafenib discontinuation for toxicity or HCC progression. The two groups were compared for demographic and clinical features...
December 16, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29246011/network-meta-analysis-of-the-efficacy-of-first-line-chemotherapy-regimens-in-patients-with-advanced-colorectal-cancer
#20
Dong-Mei Wu, Yong-Jian Wang, Shao-Hua Fan, Juan Zhuang, Zi-Feng Zhang, Qun Shan, Xin-Rui Han, Xin Wen, Meng-Qiu Li, Bin Hu, Chun-Hui Sun, Ya-Xing Bao, Hai-Juan Xiao, Lin Yang, Jun Lu, Yuan-Lin Zheng
This network meta-analysis compared the short-term and long-term efficacies of first-line chemotherapy regimens in patients with advanced colorectal cancer (CRC). The 10 regimens included folinic acid + 5-fluorouracil + oxaliplatin (FOLFOX), folinic acid + 5-fluorouracil + irinotecan (FOLFIRI), folinic acid + 5-fluorouracil + gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrexate (FFT), folinic acid + 5-fluorouracil (FF), irinotecan + oxaliplatin (IROX), raltitrexed + oxaliplatin (TOMOX), folinic acid + tegafur-uracil (FTU), raltitrexed, and capecitabine...
November 21, 2017: Oncotarget
keyword
keyword
20530
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"